Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Longeveron Inc. (NASDAQ: LGVN) SEC filings, giving investors a primary source of regulatory information about the clinical stage biotechnology company and its cellular therapy programs. Longeveron files a range of documents with the U.S. Securities and Exchange Commission, including Forms 8-K, registration statements, and other reports that describe its business, capital structure, and material events.
Recent 8-K filings have detailed topics such as public offerings of Class A common stock and warrants, an at-the-market (ATM) offering agreement, financial results for quarterly periods, changes in executive leadership and board composition, and a Nasdaq notice regarding the minimum bid price requirement for continued listing on The Nasdaq Capital Market. These filings also discuss how the company intends to use offering proceeds, including funding clinical and regulatory development of its lead mesenchymal stem cell therapy, laromestrocel (Lomecel-B), for indications like hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and pediatric dilated cardiomyopathy.
Through registration statements on Form S-1 and related amendments, Longeveron outlines the terms of securities offerings, its status as an emerging growth and smaller reporting company, and risk factors associated with its business and development plans. Investors can also review disclosures about ATM programs and material definitive agreements with placement agents.
On Stock Titan, these LGVN SEC filings are paired with AI-powered summaries that highlight key points, such as financing terms, listing compliance updates, and planned uses of capital. Users can quickly locate quarterly and annual reporting documents, transaction-related filings, and other regulatory disclosures to better understand Longeveron’s operations, funding strategy, and clinical development priorities.
Longeveron General Counsel and Secretary Paul T. Lehr reported significant insider transactions on June 23, 2025. The transactions involved:
- Acquisition of 163,043 restricted stock units (RSUs) that fully vested on the grant date
- Disposition of 64,158 shares at $1.15 per share through share withholding for tax obligations
- Following these transactions, Lehr holds 255,635 shares directly, including RSUs subject to future vesting
The Form 4 filing demonstrates substantial equity-based compensation for a key executive officer, with immediate vesting of the new RSU grant. The share withholding for tax purposes is a common practice for executive equity compensation arrangements. This insider activity provides insights into Longeveron's executive compensation structure and retention strategies.
Longeveron Inc. (LGVN) has filed a Form S-8 to register an additional 4,000,000 shares of Class A Common Stock for issuance under its Third Amended and Restated 2021 Incentive Award Plan. The new shares, which were approved by shareholders on 13 June 2025, are in addition to 1,657,441 shares previously registered on three earlier S-8 filings (February 2021, June 2023 and July 2024, all share counts adjusted for a 26 March 2024 reverse split). Accordingly, the plan now has 5,657,441 registered shares available for equity-based compensation.
The filing is submitted under General Instruction E, thereby incorporating by reference all prior S-8 registration statements and the company’s periodic reports, including the Form 10-K for the fiscal year ended 31 Dec 2024 and all Forms 10-Q/8-K filed thereafter. Buchanan Ingersoll & Rooney PC rendered the legality opinion (its attorneys collectively own 2,000 LGVN shares), and Marcum LLP provided the auditor’s consent.
Key implications for investors:
- Equity dilution risk: The 4 million newly registered shares will expand the incentive pool, increasing the potential supply of freely tradable shares as awards vest and are exercised.
- Talent retention & alignment: A larger equity pool can strengthen management and employee retention incentives by allowing additional grants.
- Shareholder oversight: Because the share increase required shareholder approval, governance processes were followed; LGVN remains a smaller reporting company and emerging growth company.
FAQ
What is the current stock price of Longeveron (LGVN)?
What is the market cap of Longeveron (LGVN)?
